miRNA vs cfDNA in Breast Cancer Screening

By Priyanka Varma

BURLINGAME, Calif.

Oct. 4th, 2022

‍

Bibliography:

1.      Sun X,Luo S, He Y, Shao Y, Liu C, Chen Q, Cui S, Liu H. Screening of the miRNAsrelated to breast cancer and identification of its target genes. Eur J GynaecolOncol. 2014;35(6):696-700. PMID: 25566594.

2.       Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., WymanS.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O’Briant K.C., AllenA., et al. Circulating microRNAs as stable blood-based markers for cancerdetection. Proc. Natl. Acad. Sci. USA. 2008;105:10513–10518.doi: 10.1073/pnas.0804549105.

3.      Stroun M., Anker P., Maurice P.,Lyautey J., Lederrey C., Beljanski M. Neoplastic characteristics of the DNAfound in the plasma of cancer patients. Oncology. 1989;46:318–322.

4.      Zou R, Loke SY, Tan VK, Quek ST,Jagmohan P, Tang YC, Madhukumar P, Tan BK, Yong WS, Sim Y, Lim SZ, Png E, LeeSYS, Chan MYP, Ho TSJ, Khoo BKJ, Wong SLJ, Thng CH, Chong BK, Teo YY, Too HP,Hartman M, Tan NC, Tan EY, Lee SC, Zhou L, Lee ASG. Development of a microRNAPanel for Classification of Abnormal Mammograms for Breast Cancer. Cancers(Basel). 2021 Apr 28;13(9):2130. doi: 10.3390/cancers13092130. PMID: 33925125;PMCID: PMC8124944.

5.     Whatis Cell-Free DNA (cfDNA)? - Seq It Out #19 - Behind the Bench(thermofisher.com)

6.      Fonseca-Sanchéz MA, Pérez-PlasenciaC, Fernández-Retana J, Arechaga-Ocampo E, Marchat LA, Rodríguez-Cuevas S,Bautista-Piña V, Arellano-Anaya ZE, Flores-Pérez A, Diaz-Chávez J,López-Camarillo C. microRNA-18b is upregulated in breast cancer and modulatesgenes involved in cell migration. Oncol Rep. 2013 Nov;30(5):2399-410. doi:10.3892/or.2013.2691. Epub 2013 Aug 22. PMID: 23970382.

7.      Frères P, Wenric S, Boukerroucha M,Fasquelle C, Thiry J, Bovy N, Struman I, Geurts P, Collignon J, Schroeder H,Kridelka F, Lifrange E, Jossa V, Bours V, Josse C, Jerusalem G. CirculatingmicroRNA-based screening tool for breast cancer. Oncotarget. 2016 Feb2;7(5):5416-28. doi: 10.18632/oncotarget.6786. PMID: 26734993; PMCID:PMC4868695.

8.      KrepelkovaI, Mrackova T, Izakova J, Dvorakova B, Chalupova L, Mikulik R, Slaby O, BartosM, Ruzicka V. Evaluation of miRNA detection methods for the analyticalcharacteristic necessary for clinical utilization. Biotechniques. 2019 Jun;66(6):277-284.doi: 10.2144/btn-2019-0021. Epub 2019 May 24. PMID: 31124705.

9.    Hammond SM. An overview of microRNAs. Adv DrugDeliv Rev. 2015 Jun 29;87:3-14. doi: 10.1016/j.addr.2015.05.001. Epub 2015 May12. PMID: 25979468; PMCID: PMC4504744.

10. WhatIs cfDNA? | Technology Networks

11. Whatis Cell-Free DNA (cfDNA)? - Seq It Out #19 - Behind the Bench(thermofisher.com)

12. Hu Z, Dong J, Wang LE, Ma H, Liu J, Zhao Y,Tang J, Chen X, Dai J, Wei Q, Zhang C, Shen H. Serum microRNA profiling andbreast cancer risk: the use of miR-484/191 as endogenous controls.Carcinogenesis. 2012 Apr;33(4):828-34. doi: 10.1093/carcin/bgs030. Epub 2012Feb 1. PMID: 22298638.

13. Garcia, J., Kamps-Hughes, N., Geiguer, F. etal. Sensitivity, specificity, and accuracy of a liquid biopsy approachutilizing molecular amplification pools. Sci Rep 11,10761 (2021). https://doi.org/10.1038/s41598-021-89592-8

14. Treerattrakoon K, Roeksrungruang P, Dharakul T,Japrung D, Faulds K, Graham D, Bamrungsap S. Detection of a miRNA biomarker forcancer diagnosis using SERS tags and magnetic separation. Anal Methods. 2022May 27;14(20):1938-1945. doi: 10.1039/d2ay00210h. PMID: 35441184.

15. Schwarzenbach H, Pantel K. Circulating DNA asbiomarker in breast cancer. Breast Cancer Res. 2015 Oct 9;17(1):136. doi:10.1186/s13058-015-0645-5. PMID: 26453190; PMCID: PMC4599311.